Pioneering technology

Xerion’s technology improves the effectiveness of conventional radiotherapy while minimising side-effects. The company’s Oxilia nanoparticles have a physical mode of action and offer the ability to improve treatment of a wide range of solid tumours.

A strong background, a strong future

Spun out from Oxford University in 2015 following eight years of research, Xerion Healthcare is based and founded in the UK to develop and commercialise Oxilia treatment.

Best-in-class nanomedicine

  • Oxilia has a physical mode of action and Best-in-class radio sensitiser delivering unparalleled dose enhancement of radiotherapy
  • Targeting a wide range of poorly treated solid tumours – initial focus on head & neck cancer
  • Regulated as a class III medical device

Strong IP position

  • Granted patents: EU, US, China, Japan
  • Patent protection to 2037
  • Clear freedom-to-operate position
  • Extensive manufacturing know-how

The Xerion Team

Xerion’s management team has extensive commercial experience combined with pioneering nanotechnology expertise and support from world-leading oncologists.

Justin Stebbing

Prof Justin Stebbing, Chairman

Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College

Read more
Ian George

Ian George, CEO

Tech investor, extensive experience in developing & raising funds for healthcare companies

Read more
Gareth Wakefield

Gareth Wakefield, CTO

Co-founded Oxonica, over 16 years experience in materials & nano-technology start-ups

Read more
Martin Gardener

Martin Gardener, Head of Production

17 years experience in nanoparticle synthesis

Read more
Matt Stock

Matt Stock, Head of Research

Six years industrial experience in chemistry/engineering sectors

Read more
Megan Adiar

Megan Adair, Quality Manager

Eight years experience in quality assurance and quality control

Read more
Read about us in the press

Company Timeline

2015

Xerion is founded to bring Oxilia to market, based on patent filed in 2010

Xerion files patent to expand the scope of technology and its applications

August 2015 - Seed investment from New Wave Ventures & Parkwalk Advisors

2017

Innovate UK Biomedical Catalyst early stage grant awarded

Xerion’s technology efficacy and safety demonstrated in vivo

December 2017 - Investment from Oxford Sciences Innovation

2018

Innovate UK Biomedical catalyst feasibility grant awarded

April 2018 - Prof Justin Stebbing appointed to company Chair

2019

September - Innovate UK Biomedical Catalyst late stage grant awarded to support product scale-up & pre-clinical testing

X Icon